Discover 12 paid clinical trials in Aberdeen, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 12
Active & Responsive
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
for
Intestinal Neoplasms, Gastrointestinal Neoplasms,
Location: Aberdeen SD, Pierre SD, Mitchell SD, Marshall MN,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07222800
Phase 3, Recruiting
Active & Responsive
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
for
Plasma Cell Myeloma
Location: Aberdeen SD, Jamestown ND, Fargo ND, Bismarck ND,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT05561387
Phase 3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Aberdeen SD, Jamestown ND, Pierre SD, Fargo ND,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase 3, Recruiting
Avera Cancer Sequencing and Analytics Protocol (ASAP)
for
Cancer, Cancer Diagnosis, Early Detection of Cancer,
Location: Aberdeen SD, Pierre SD, Mitchell SD, Marshall MN,
Sponsor: Avera McKennan Hospital & University Health Center
Sex: All
Age: 18+
Code: NCT05142033
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
for
Locally Advanced Urothelial Carcinoma,
Location: Aberdeen SD, Pierre SD, Mitchell SD, Fargo ND,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06524544
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Location: Aberdeen SD, Pierre SD, Mitchell SD, Fargo ND,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 65+
Code: NCT07321652
Phase 3, Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
for
Prostate Cancer Metastatic
Location: Aberdeen SD, Pierre SD, Mitchell SD, Marshall MN,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06136624
Phase 3, Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
for
Breast Cancer
Location: Aberdeen SD, Pierre SD, Mitchell SD, Marshall MN,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07405801
Phase 2, Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Aberdeen SD, Pierre SD, Mitchell SD, Marshall MN,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05947851
Phase 3, Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for
Pancreatic Acinar Cell Carcinoma,
Location: Aberdeen SD, Pierre SD, Fargo ND, Bismarck ND,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04858334
Phase 2, Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),
Location: Aberdeen SD, Pierre SD, Mitchell SD, Marshall MN,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06136650
Phase 3, Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
for
Breast Cancer, Early Breast Cancer
Location: Aberdeen SD, Pierre SD, Irving TX, Winston-Salem NC